Fulvestrant vs aromatase inhibitors in advanced disease

Fulvestrant and aromatase inhibitors are both hormone treatments for hormone receptor positive breast cancer, but they work in different ways. Aromatase inhibitors, such as letrozole, anastrozole and exemestane, are daily tablets that lower the amount of oestrogen the body makes after the menopause. Fulvestrant is a monthly injection that attaches to the oestrogen receptor on cancer cells and breaks it down, so the cancer cannot respond to whatever oestrogen remains. Both are used for advanced disease in women who are postmenopausal or whose ovaries are switched off. In a large trial called FALCON, among women who had never had hormone treatment before, fulvestrant on its own kept the cancer controlled for somewhat longer than anastrozole on its own, with the clearest difference in women whose cancer had not spread to the liver or lungs. Today, however, most people starting treatment for advanced disease receive a hormone treatment combined with a CDK4/6 inhibitor, and the choice of partner depends largely on earlier treatment. An aromatase inhibitor is often chosen when the cancer has not grown on one before. Fulvestrant is often chosen when the cancer came back during or soon after aromatase inhibitor tablets, or when it has grown on them. Tablet versus injection, side effects, cost and test results such as ESR1 mutations also shape the decision.

Different ways of blocking oestrogen

Aromatase inhibitors lower oestrogen levels; fulvestrant blocks and removes the receptor the cancer depends on.

Earlier treatment usually decides

What you have already had, and how the cancer behaved on it, matters more than which medicine is stronger in general.

Both are often combined

Either medicine may be paired with a CDK4/6 inhibitor or another targeted tablet.

There is rarely a single right answer, and reasonable oncologists may weigh things differently.

Combinations changed the picture

FALCON compared the medicines on their own. With a CDK4/6 inhibitor added, a later trial called PARSIFAL found fulvestrant and letrozole worked similarly as a first treatment.

Neither lasts forever

In advanced disease, hormone treatments usually stop working in time, and another option follows.

Practical factors are valid

Travel, cost and dislike of injections are legitimate reasons to prefer one option.

What this page cannot tell you

It cannot say which medicine is right for you. That depends on your history and test results.

A few focused questions help you understand the recommendation and share your preferences.

Why this option for me?

Ask how your earlier treatment, where the cancer is and any test results shaped the choice.

What would we do next?

Knowing the likely next step if this treatment stops working can make the plan feel less uncertain.

How will we check it is working?

Ask when scans will happen and what changes would lead to a switch.

What will it cost and involve?

Clinic visits, blood tests and partner tablet costs differ between plans, and it is fine to ask.